{
    "clinical_study": {
        "@rank": "50202", 
        "acronym": "MeT1", 
        "arm_group": [
            {
                "arm_group_label": "Metformin", 
                "arm_group_type": "Experimental", 
                "description": "Drug: Metformin"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Six week intervention: study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk\n      in type 1 diabetes (T1D). The purpose of this study is to measure the effect of metformin on\n      insulin sensitivity, vascular function and compliance, and mitochondrial function in T1D.\n      The long term goal is to identify novel non-glycemic approaches to managing cardiovascular\n      disease risk in T1D. The results of this study may validate a novel approach to T1D\n      treatment that could significantly improve current management of cardiovascular disease risk\n      in this high risk population."
        }, 
        "brief_title": "Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. age 20-59 years of age,\n\n          2. type 1 diabetes based on antibody-positivity, rapid persistent conversion to insulin\n             requirement after diagnosis, absent C-peptide, or DKA at diagnosis, or a clinical\n             course consistent with T1D,\n\n          3. HbA1c 6.0 - 9.5, and\n\n          4. willing and able to commit to two 6 week-long periods of blinded medication followed\n             by hyperinsulinemic euglycemic clamp, vascular testing, and muscle biopsies.\n\n        Exclusion Criteria:\n\n          -  Any comorbid condition associated with inflammation, IR, or dyslipidemia including\n             cancer, heart failure, active or end stage liver disease, kidney disease, or\n             rheumatological disease;\n\n          -  Tobacco use;\n\n          -  Pregnancy or women who are breastfeeding;\n\n          -  Steroid use\n\n          -  Scheduled strenuous physical activity >3 days a week.\n\n          -  Angina, known CAD, or any other cardiovascular or pulmonary disease\n\n          -  A history of COPD or asthma\n\n          -  Presence of systolic blood pressure >190 at rest or >250 with exercise or diastolic\n             pressure >95 at rest or >105 with exercise\n\n          -  Untreated thyroid disease\n\n          -  Proteinuria (urine protein >200 mg/dl) or a creatinine > 1.5 mg/dl (males) or 1.4\n             mg/dL (females), suggestive of severe renal disease\n\n          -  Severe Proliferative retinopathy.\n\n          -  Niacin treatment\n\n          -  Administration of experimental agent for T1D within 30 days prior to screening\n\n          -  Recent (prior 6 months) or current metformin or thiazolidenedione use\n\n          -  Hypoglycemia unawareness or recurrent severe hypoglycemia (no symptoms of\n             hypoglycemia with FSBS<40 and episodes of this severity >1 per week)\n\n          -  Weight instability (weight change >5% in last 6 months)\n\n          -  History of any organ transplant, including islet cell transplant\n\n          -  Current or prior infection with HIV, hepatitis B or hepatitis C or hepatic\n             -insufficiency (AST or ALT > 2x the upper limits of normal)\n\n          -  Any condition, medical or otherwise that would, in the opinion of the investigator,\n             prevent complete participation in the study, or that would pose a significant hazard\n             to the subject\n\n          -  History of substance abuse within the 12 months prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "59 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813929", 
            "org_study_id": "11-0693"
        }, 
        "intervention": [
            {
                "arm_group_label": "Metformin", 
                "description": "Six week intervention: study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": "glucophage"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Six-week intervention: Placebo will be given in a forced uptitration with 500 mg once daily for one week, twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes", 
            "Insulin", 
            "Metformin", 
            "Vascular", 
            "Vessels", 
            "Type 1"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "nathaniel.solis@ucdenver.edu", 
                "last_name": "Nathaniel Solis, BS", 
                "phone": "303-724-6634"
            }, 
            "contact_backup": {
                "email": "leah.herlache@ucdenver.edu", 
                "last_name": "Leah Herlache, MS", 
                "phone": "720-848-6688"
            }, 
            "facility": {
                "address": {
                    "city": "Aurora", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80045"
                }, 
                "name": "University of Colorado Denver"
            }, 
            "investigator": {
                "last_name": "Irene Schauer, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes", 
        "overall_contact": {
            "email": "nicholas.birdsey@ucdenver.edu", 
            "last_name": "Nicholas Birdsey, BS", 
            "phone": "303-877-3511"
        }, 
        "overall_contact_backup": {
            "email": "leah.herlache@ucdenver.edu", 
            "last_name": "Leah Herlache, MS", 
            "phone": "720-848-6688"
        }, 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Irene Schauer, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Determine the effect of metformin on insulin sensitivity in T1D.", 
                "measure": "Insulin Sensitivitybu hyperinsulinemic euglycemic clamp", 
                "safety_issue": "No", 
                "time_frame": "end of each 6 week intervention period"
            }, 
            {
                "description": "Measure of endothelial function", 
                "measure": "flow-mediated brachial artery dilation", 
                "safety_issue": "No", 
                "time_frame": "End of each 6 week intervention period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813929"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PWV and AI by Sphygmacor", 
                "measure": "arterial stiffness", 
                "safety_issue": "No", 
                "time_frame": "End of each 6 week intervention period"
            }, 
            {
                "description": "Mito content and electron transport chain complexes, oxygen consumption with various substrates and max uncoupled O2 consumption. oxidant generation", 
                "measure": "Mitochondrial measures", 
                "safety_issue": "No", 
                "time_frame": "End of each 6 week intervention period"
            }, 
            {
                "description": "glucose, fatty acids, triglycerides, cholesterol, glycerol, insulin, lactate, counterregulatory hormones, IL6, TNF alpha, hsCRP, PAI-1, adiponection, TBARs, ICAM, endothelin-1, GSSG:GSH ratio", 
                "measure": "Metabolic, inflammatory, vascular, and oxidative stress markers", 
                "safety_issue": "No", 
                "time_frame": "End of each 6 week intervention period"
            }, 
            {
                "description": "measure of autonomic function", 
                "measure": "heart rate variability", 
                "safety_issue": "No", 
                "time_frame": "End of each 6 week intervention period"
            }
        ], 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "collaborator": {
                "agency": "Department of Veterans Affairs", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}